Marketwire  ALDA Pharmaceuticals Corp.  October 10, 2007 - 10:32:27 AM  ALDA Receives Notice of Allowance for Australian Patent   VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 10, 2007) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") has been notified that the Australian Patent Office has accepted ALDA's patent application that describes the composition and production methods for ALDA's T36(R) formulation.  As in the case of the US and Chinese patent applications which were also recently approved and announced by the company in news releases dated June 26 and June 28, 2007, respectively, the Australian patent application covers the process for making the T36(R) formulation as well as the formulation itself. The components of the T36(R) formulation act synergistically to disrupt the physical structure of the infectious organisms rather than interfering with their metabolic pathways. This provides a high degree of efficacy and safety, prevents microbial resistance and causes no side effects or toxicity to patients.  Dr. Terrance Owen, President & CEO, states, "Notification that the patent will now be issued in Australia provides further comfort that our intellectual property is very robust. We are gratified to see rapid allowance of the patent applications in a number of jurisdictions. Clearly, ALDA's T36(R) formulation is unique and is becoming a significant asset to the company."  About ALDA Pharmaceuticals Corp.  ALDA is focused on the development of infection control therapeutics derived from its patent-pending T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH.   FOR FURTHER INFORMATION PLEASE CONTACT:   ALDA Pharmaceuticals Corp. Terrance G. Owen, Ph.D., MBA President, CEO and Director (604) 521-8300       ALDA Pharmaceuticals Corp. - Distribution & Sales Peter Chen  (604) 521-8300 Ext. 3 (604) 521-8322 (FAX) Email: peter_chen@aldacorp.com.     ALDA Pharmaceuticals Corp. - Investor Relations Scott Young  (604) 288-7222  Email: syoung@freeformcom.com Website: www.aldacorp.com   The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.